Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide

  • Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6. doi: 10.1128/AAC.48.7.2693-2696.2004.
Chang-Jer Wu  1 ,  Jia-Tsrong Jan ,  Chi-Min Chen ,  Hsing-Pang Hsieh ,  Der-Ren Hwang ,  Hwan-Wun Liu ,  Chiu-Yi Liu ,  Hui-Wen Huang ,  Su-Chin Chen ,  Cheng-Fong Hong ,  Ren-Kuo Lin ,  Yu-Sheng Chao ,  John T A Hsu
Affiliations
  • 1. Institute of Preventive Medicine, National Defense Medical College, National Defense University, Taipei, Taiwan.
PMID: 15215127 DOI: 10.1128/AAC.48.7.2693-2696.2004
Abstract

Antiviral agents are urgently needed to fight severe acute respiratory syndrome (SARS). We showed that niclosamide, an existing antihelminthic drug, was able to inhibit replication of a newly discovered coronavirus, SARS-CoV; viral antigen synthesis was totally abolished at a niclosamide concentration of 1.56 microM, as revealed by immunoblot analysis. Thus, niclosamide represents a promising drug candidate for the effective treatment of SARS-CoV Infection.

Products